Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment
•We assess cytokine levels as a prognostic marker of early hepatocellular carcinoma.•A low serum interleukin-6 level is an independent risk factor for HCC recurrence.•Patients with low interleukin-6 should be cautiously followed-up after treatment. We aimed to investigate the use of novel serum biom...
Gespeichert in:
| Veröffentlicht in: | Cytokine (Philadelphia, Pa.) Pa.), 2015-06, Vol.73 (2), p.245-252 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 252 |
|---|---|
| container_issue | 2 |
| container_start_page | 245 |
| container_title | Cytokine (Philadelphia, Pa.) |
| container_volume | 73 |
| creator | Cho, Hyo Jung Kim, Soon Sun Ahn, Seun Joo Park, Sun Young Park, Joo Han Kim, Jae Keun Wang, Hee Jung Cheong, Jae Youn Cho, Sung Won |
| description | •We assess cytokine levels as a prognostic marker of early hepatocellular carcinoma.•A low serum interleukin-6 level is an independent risk factor for HCC recurrence.•Patients with low interleukin-6 should be cautiously followed-up after treatment.
We aimed to investigate the use of novel serum biomarkers for predicting the recurrence and survival of patients with hepatitis B virus (HBV)-related early hepatocellular carcinoma (HCC) after hepatic resection or radiofrequency ablation (RFA).
One hundred and five patients with HBV-related HCC, who fulfilled the Milan criteria without vascular invasion and underwent hepatic resection or RFA, were followed-up for a median duration of 52months. Pretreatment serum concentrations of 16 cytokines including interleukin-6 (IL-6) were measured by using a Luminex 200 system. The measured serum cytokines and several clinical factors were analyzed retrospectively.
Univariate analysis showed that patients with lower pretreatment serum levels of IL-10, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-α had significantly shorter disease-free survival (DFS) than those with higher levels. Multivariate analysis revealed that a low serum IL-6 level (⩽33.00pg/mL; hazard ratio [HR]=5.39; 95% confidence interval [CI]=1.27–22.93; P=0.022), low platelet count ( |
| doi_str_mv | 10.1016/j.cyto.2015.02.027 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1681908875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1043466615001052</els_id><sourcerecordid>1681908875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-548ecfa94acbdc41d61360198b20662d06cce765886dba492a24ebf12ba77de63</originalsourceid><addsrcrecordid>eNp9Uc1u3CAYRFWjJk36Aj1UHHvxFrANttRLG_VPWqmX5IwwfNaysc32A3aVN-pjBnfTHiuNBB_MDGiGkLecbTjj8sN-Yx9T2AjG2w0TBeoFueKslxVjon657pu6aqSUl-R1jHvGWF8r9Ypcilb1ivfsivzehhONgHmmfkmAE-QHv1SSTnCEKVJTQA8Iztvkj0Bngw-ANIwUwWZEWCwUJT2Y5GFJkZ582tEdrHPykX6mR485FvZkErjzTbAwTXkySK1B65cwG3raBZoXB3gqNrRYmz_vJQST5nJ0Qy5GM0V487xek_uvX-5uv1fbn99-3H7aVrZuZarapgM7mr4xdnC24U7yWjLed4NgUgrHpLWgZNt10g2m6YURDQwjF4NRyoGsr8n7s-8Bw68MMenZx_W_ZoGQo-ayK8F1nWoLVZypFkOMCKM-oC8BPWrO9NqQ3uu1Ib02pJkoUEX07tk_DzO4f5K_lRTCxzOhxA9HD6ij9WvMzpfIk3bB_8__CavJp10</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1681908875</pqid></control><display><type>article</type><title>Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cho, Hyo Jung ; Kim, Soon Sun ; Ahn, Seun Joo ; Park, Sun Young ; Park, Joo Han ; Kim, Jae Keun ; Wang, Hee Jung ; Cheong, Jae Youn ; Cho, Sung Won</creator><creatorcontrib>Cho, Hyo Jung ; Kim, Soon Sun ; Ahn, Seun Joo ; Park, Sun Young ; Park, Joo Han ; Kim, Jae Keun ; Wang, Hee Jung ; Cheong, Jae Youn ; Cho, Sung Won</creatorcontrib><description>•We assess cytokine levels as a prognostic marker of early hepatocellular carcinoma.•A low serum interleukin-6 level is an independent risk factor for HCC recurrence.•Patients with low interleukin-6 should be cautiously followed-up after treatment.
We aimed to investigate the use of novel serum biomarkers for predicting the recurrence and survival of patients with hepatitis B virus (HBV)-related early hepatocellular carcinoma (HCC) after hepatic resection or radiofrequency ablation (RFA).
One hundred and five patients with HBV-related HCC, who fulfilled the Milan criteria without vascular invasion and underwent hepatic resection or RFA, were followed-up for a median duration of 52months. Pretreatment serum concentrations of 16 cytokines including interleukin-6 (IL-6) were measured by using a Luminex 200 system. The measured serum cytokines and several clinical factors were analyzed retrospectively.
Univariate analysis showed that patients with lower pretreatment serum levels of IL-10, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-α had significantly shorter disease-free survival (DFS) than those with higher levels. Multivariate analysis revealed that a low serum IL-6 level (⩽33.00pg/mL; hazard ratio [HR]=5.39; 95% confidence interval [CI]=1.27–22.93; P=0.022), low platelet count (<100×109/L; HR=2.23; 95% CI=1.28–3.89; P=0.005), and low serum albumin level (⩽3.5g/L; HR=2.26; 95% CI=1.28–3.97; P=0.005) had a negative prognostic impact on DFS. In the analysis for overall survival, a low serum platelet level (<100×109/L; HR=2.80; 95% CI=1.31–5.99; P=0.008) and multiple tumor (⩾2; HR=4.05; 95% CI=1.56–10.48; P=0.004) showed a negative prognostic impact on the overall survival.
A low serum IL-6 level is, in addition to low platelet count and low serum albumin level, an independent prognostic factor for DFS in patients with HBV-related early HCC who underwent hepatic resection or RFA with curative intention.</description><identifier>ISSN: 1043-4666</identifier><identifier>EISSN: 1096-0023</identifier><identifier>DOI: 10.1016/j.cyto.2015.02.027</identifier><identifier>PMID: 25797190</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - surgery ; Carcinoma, Hepatocellular - virology ; Catheter Ablation ; Cytokine ; Disease-Free Survival ; Female ; Hepatitis B virus - physiology ; Hepatitis B, chronic ; Hepatocellular carcinoma ; Humans ; Interleukin-6 - blood ; Kaplan-Meier Estimate ; Liver Neoplasms - blood ; Liver Neoplasms - surgery ; Liver Neoplasms - virology ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Recurrence, Local - blood ; Prognosis ; Risk Factors</subject><ispartof>Cytokine (Philadelphia, Pa.), 2015-06, Vol.73 (2), p.245-252</ispartof><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-548ecfa94acbdc41d61360198b20662d06cce765886dba492a24ebf12ba77de63</citedby><cites>FETCH-LOGICAL-c356t-548ecfa94acbdc41d61360198b20662d06cce765886dba492a24ebf12ba77de63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cyto.2015.02.027$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25797190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cho, Hyo Jung</creatorcontrib><creatorcontrib>Kim, Soon Sun</creatorcontrib><creatorcontrib>Ahn, Seun Joo</creatorcontrib><creatorcontrib>Park, Sun Young</creatorcontrib><creatorcontrib>Park, Joo Han</creatorcontrib><creatorcontrib>Kim, Jae Keun</creatorcontrib><creatorcontrib>Wang, Hee Jung</creatorcontrib><creatorcontrib>Cheong, Jae Youn</creatorcontrib><creatorcontrib>Cho, Sung Won</creatorcontrib><title>Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment</title><title>Cytokine (Philadelphia, Pa.)</title><addtitle>Cytokine</addtitle><description>•We assess cytokine levels as a prognostic marker of early hepatocellular carcinoma.•A low serum interleukin-6 level is an independent risk factor for HCC recurrence.•Patients with low interleukin-6 should be cautiously followed-up after treatment.
We aimed to investigate the use of novel serum biomarkers for predicting the recurrence and survival of patients with hepatitis B virus (HBV)-related early hepatocellular carcinoma (HCC) after hepatic resection or radiofrequency ablation (RFA).
One hundred and five patients with HBV-related HCC, who fulfilled the Milan criteria without vascular invasion and underwent hepatic resection or RFA, were followed-up for a median duration of 52months. Pretreatment serum concentrations of 16 cytokines including interleukin-6 (IL-6) were measured by using a Luminex 200 system. The measured serum cytokines and several clinical factors were analyzed retrospectively.
Univariate analysis showed that patients with lower pretreatment serum levels of IL-10, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-α had significantly shorter disease-free survival (DFS) than those with higher levels. Multivariate analysis revealed that a low serum IL-6 level (⩽33.00pg/mL; hazard ratio [HR]=5.39; 95% confidence interval [CI]=1.27–22.93; P=0.022), low platelet count (<100×109/L; HR=2.23; 95% CI=1.28–3.89; P=0.005), and low serum albumin level (⩽3.5g/L; HR=2.26; 95% CI=1.28–3.97; P=0.005) had a negative prognostic impact on DFS. In the analysis for overall survival, a low serum platelet level (<100×109/L; HR=2.80; 95% CI=1.31–5.99; P=0.008) and multiple tumor (⩾2; HR=4.05; 95% CI=1.56–10.48; P=0.004) showed a negative prognostic impact on the overall survival.
A low serum IL-6 level is, in addition to low platelet count and low serum albumin level, an independent prognostic factor for DFS in patients with HBV-related early HCC who underwent hepatic resection or RFA with curative intention.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>Catheter Ablation</subject><subject>Cytokine</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hepatitis B virus - physiology</subject><subject>Hepatitis B, chronic</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Interleukin-6 - blood</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver Neoplasms - virology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Prognosis</subject><subject>Risk Factors</subject><issn>1043-4666</issn><issn>1096-0023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uc1u3CAYRFWjJk36Aj1UHHvxFrANttRLG_VPWqmX5IwwfNaysc32A3aVN-pjBnfTHiuNBB_MDGiGkLecbTjj8sN-Yx9T2AjG2w0TBeoFueKslxVjon657pu6aqSUl-R1jHvGWF8r9Ypcilb1ivfsivzehhONgHmmfkmAE-QHv1SSTnCEKVJTQA8Iztvkj0Bngw-ANIwUwWZEWCwUJT2Y5GFJkZ582tEdrHPykX6mR485FvZkErjzTbAwTXkySK1B65cwG3raBZoXB3gqNrRYmz_vJQST5nJ0Qy5GM0V487xek_uvX-5uv1fbn99-3H7aVrZuZarapgM7mr4xdnC24U7yWjLed4NgUgrHpLWgZNt10g2m6YURDQwjF4NRyoGsr8n7s-8Bw68MMenZx_W_ZoGQo-ayK8F1nWoLVZypFkOMCKM-oC8BPWrO9NqQ3uu1Ib02pJkoUEX07tk_DzO4f5K_lRTCxzOhxA9HD6ij9WvMzpfIk3bB_8__CavJp10</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Cho, Hyo Jung</creator><creator>Kim, Soon Sun</creator><creator>Ahn, Seun Joo</creator><creator>Park, Sun Young</creator><creator>Park, Joo Han</creator><creator>Kim, Jae Keun</creator><creator>Wang, Hee Jung</creator><creator>Cheong, Jae Youn</creator><creator>Cho, Sung Won</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201506</creationdate><title>Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment</title><author>Cho, Hyo Jung ; Kim, Soon Sun ; Ahn, Seun Joo ; Park, Sun Young ; Park, Joo Han ; Kim, Jae Keun ; Wang, Hee Jung ; Cheong, Jae Youn ; Cho, Sung Won</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-548ecfa94acbdc41d61360198b20662d06cce765886dba492a24ebf12ba77de63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>Catheter Ablation</topic><topic>Cytokine</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hepatitis B virus - physiology</topic><topic>Hepatitis B, chronic</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Interleukin-6 - blood</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver Neoplasms - virology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Prognosis</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cho, Hyo Jung</creatorcontrib><creatorcontrib>Kim, Soon Sun</creatorcontrib><creatorcontrib>Ahn, Seun Joo</creatorcontrib><creatorcontrib>Park, Sun Young</creatorcontrib><creatorcontrib>Park, Joo Han</creatorcontrib><creatorcontrib>Kim, Jae Keun</creatorcontrib><creatorcontrib>Wang, Hee Jung</creatorcontrib><creatorcontrib>Cheong, Jae Youn</creatorcontrib><creatorcontrib>Cho, Sung Won</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cytokine (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cho, Hyo Jung</au><au>Kim, Soon Sun</au><au>Ahn, Seun Joo</au><au>Park, Sun Young</au><au>Park, Joo Han</au><au>Kim, Jae Keun</au><au>Wang, Hee Jung</au><au>Cheong, Jae Youn</au><au>Cho, Sung Won</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment</atitle><jtitle>Cytokine (Philadelphia, Pa.)</jtitle><addtitle>Cytokine</addtitle><date>2015-06</date><risdate>2015</risdate><volume>73</volume><issue>2</issue><spage>245</spage><epage>252</epage><pages>245-252</pages><issn>1043-4666</issn><eissn>1096-0023</eissn><abstract>•We assess cytokine levels as a prognostic marker of early hepatocellular carcinoma.•A low serum interleukin-6 level is an independent risk factor for HCC recurrence.•Patients with low interleukin-6 should be cautiously followed-up after treatment.
We aimed to investigate the use of novel serum biomarkers for predicting the recurrence and survival of patients with hepatitis B virus (HBV)-related early hepatocellular carcinoma (HCC) after hepatic resection or radiofrequency ablation (RFA).
One hundred and five patients with HBV-related HCC, who fulfilled the Milan criteria without vascular invasion and underwent hepatic resection or RFA, were followed-up for a median duration of 52months. Pretreatment serum concentrations of 16 cytokines including interleukin-6 (IL-6) were measured by using a Luminex 200 system. The measured serum cytokines and several clinical factors were analyzed retrospectively.
Univariate analysis showed that patients with lower pretreatment serum levels of IL-10, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-α had significantly shorter disease-free survival (DFS) than those with higher levels. Multivariate analysis revealed that a low serum IL-6 level (⩽33.00pg/mL; hazard ratio [HR]=5.39; 95% confidence interval [CI]=1.27–22.93; P=0.022), low platelet count (<100×109/L; HR=2.23; 95% CI=1.28–3.89; P=0.005), and low serum albumin level (⩽3.5g/L; HR=2.26; 95% CI=1.28–3.97; P=0.005) had a negative prognostic impact on DFS. In the analysis for overall survival, a low serum platelet level (<100×109/L; HR=2.80; 95% CI=1.31–5.99; P=0.008) and multiple tumor (⩾2; HR=4.05; 95% CI=1.56–10.48; P=0.004) showed a negative prognostic impact on the overall survival.
A low serum IL-6 level is, in addition to low platelet count and low serum albumin level, an independent prognostic factor for DFS in patients with HBV-related early HCC who underwent hepatic resection or RFA with curative intention.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25797190</pmid><doi>10.1016/j.cyto.2015.02.027</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-4666 |
| ispartof | Cytokine (Philadelphia, Pa.), 2015-06, Vol.73 (2), p.245-252 |
| issn | 1043-4666 1096-0023 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1681908875 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Biomarkers, Tumor - blood Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - surgery Carcinoma, Hepatocellular - virology Catheter Ablation Cytokine Disease-Free Survival Female Hepatitis B virus - physiology Hepatitis B, chronic Hepatocellular carcinoma Humans Interleukin-6 - blood Kaplan-Meier Estimate Liver Neoplasms - blood Liver Neoplasms - surgery Liver Neoplasms - virology Male Middle Aged Multivariate Analysis Neoplasm Recurrence, Local - blood Prognosis Risk Factors |
| title | Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A43%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20serum%20interleukin-6%20levels%20as%20a%20predictive%20marker%20of%20recurrence%20in%20patients%20with%20hepatitis%20B%20virus%20related%20hepatocellular%20carcinoma%20who%20underwent%20curative%20treatment&rft.jtitle=Cytokine%20(Philadelphia,%20Pa.)&rft.au=Cho,%20Hyo%20Jung&rft.date=2015-06&rft.volume=73&rft.issue=2&rft.spage=245&rft.epage=252&rft.pages=245-252&rft.issn=1043-4666&rft.eissn=1096-0023&rft_id=info:doi/10.1016/j.cyto.2015.02.027&rft_dat=%3Cproquest_cross%3E1681908875%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1681908875&rft_id=info:pmid/25797190&rft_els_id=S1043466615001052&rfr_iscdi=true |